BIOTRONIK Blog

Explore our latest insightful interviews and articles

Patient reading on the iPad

Blog Stories

Filter and Search

46 blog articles
Blog

“I Now Know What Really Matters in Life”

Around 49 million people in the EU suffer from cardiovascular diseases. Here, Coronary Artery Disease (CAD) accounts for the major share of the diseases. In this context, narrowing of vessels by atherosclerotic processes is closely linked to an unhealthy lifestyle. This was also the case for the North Rhine-Westphalian deacon Rainer Beerhenke. After successful stent placement and a bypass surgery in 2021, the 58-year-old is again living life to the full and is one of the first patients to take part in the EU-funded TIMELY project, which aims to improve the range of therapies for CAD patients.

Subscribe for our News

I prefer to be contacted by
*Fields are mandatory.

Latest Press Releases

Show all press releases
BERLIN, Germany
Press Release

First Implant of Amvia Sky in Europe, the World’s First Pacemaker Approved for LBBAP*

The first implant in Europe of BIOTRONIK’s latest pacemaker and CRT-P generation was conducted in early August by Prof. Dr. Jan De Pooter at the University Hospital Ghent in Belgium. The patient who received an Amvia Sky dual chamber pacemaker device was a 68-year-old man suffering from paroxysmal AV-block strongly limiting his physical efforts. “The implantation went on straightforward and very smoothly,” commented Prof. De Pooter after the procedure. “LBBAP enables pacing in a very natural, physiological way, benefiting the patient by offering physiological pacing and minimizing the risk for
BERLIN, Germany
Press Release

AI-Supported Telemedicine Platform Aims to Improve the Health of Patients After Myocardial Infarction and Prevent Reinfarctions

The TIMELY consortium announced today the enrollment of the first patient in the randomized controlled clinical TIMELY trial. The TIMELY study investigates to what extent the AI-supported TIMELY platform improves the health of myocardial infarction (MI) patients and other patients with coronary heart disease after cardiac rehabilitation. Around 1.8 million people in the European Union die each year from coronary heart disease. 1 To prevent reinfarctions, patients receive cardiac rehabilitation to support necessary changes in lifestyle habits, such as diet and increased physical activity
COPENHAGEN, Denmark
Press Release

BIOLUX P-III BENELUX All-Comers Registry Demonstrates Safety and Efficacy of BIOTRONIK’s Drug-Coated Balloon in Isolated Popliteal Lesions at 24 Months

BIOTRONIK announced the two-year-results from the BIOLUX P-III BENELUX all-comers registry, presented by Principal Investigator Prof. Frank Vermassen at CIRSE 2023 in Copenhagen, Denmark. 1 The prospective, international, multicenter post-market registry evaluated the safety and efficacy of the Passeo ®-18 Lux ® drug-coated balloon (DCB) catheter in isolated popliteal artery lesions. This indication is considered a difficult vessel bed to treat due to its biomechanical constraints that usually preclude the placement of stents. BIOLUX P-III BENELUX registry enrolled 99 patients in Belgium, the

Press Contact